How does leuprolide differ from natural GnRH?

Leuprolide is a synthetic analogue designed to be more potent and resistant to degradation, allowing it to induce receptor desensitization through continuous stimulation.

Why does testosterone increase at the start of treatment?

The initial 'flare' occurs because the drug first stimulates the pituitary to release LH and FSH before the receptors become desensitized.

Is leuprolide effective when taken orally?

No, leuprolide is a peptide and is destroyed by digestive enzymes in the stomach; it must be administered via injection.

What is the purpose of depot formulations?

Depot formulations allow for the slow, sustained release of the medication, maintaining therapeutic levels over several weeks or months.

Is the suppression of sex hormones permanent?

Clinical studies indicate that the suppression of fertility and sex steroid production is generally reversible upon discontinuation of the drug.

Back to Library

Last reviewed: October 2026

Leuprolide

Endocrine / Hormonal|Gonadotropin-releasing hormone (GnRH) receptor agonist

Also known as: Leuprorelin

Evidence Snapshot

PubMed-Indexed Literature

2351 exact-name search results

References Reviewed

10 indexed references used for this page

Molecular Record

PubChem CID 657181

Evidence Scope

The clinical evidence for leuprolide is extensive, primarily derived from decades of use in oncology and reproductive endocrinology.

Key Takeaways

Leuprolide is a synthetic nonapeptide analogue of naturally occurring GnRH.
Continuous administration leads to profound suppression of the hypothalamic-pituitary-gonadal (HPG) axis.
Initial treatment causes a transient 'flare' of gonadotropins and sex steroids before suppression is achieved.
Clinical applications include advanced prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty.
The drug is not orally active and requires parenteral administration, often via depot formulations for sustained release.

Table of Contents

1.Overview

Leuprolide is a synthetic analogue of gonadotropin-releasing hormone (GnRH), a decapeptide that regulates the hypothalamic-pituitary-gonadal (HPG) axis. By modifying the structure of natural GnRH, leuprolide achieves higher potency and a longer half-life, allowing it to serve as a powerful tool for medical castration and the suppression of sex steroid-dependent conditions.

2.Mechanism of Action

The mechanism of leuprolide is biphasic. Initially, the drug binds to GnRH receptors in the anterior pituitary, triggering a surge in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This 'flare' effect can temporarily increase circulating testosterone in men or estrogen in women.

3.Why Researchers Study It

Research into leuprolide continues to evolve, moving beyond its traditional role in prostate cancer and reproductive disorders. Current investigations explore its potential in neurodegenerative conditions, such as Alzheimer's disease, and its use in combination therapies to improve survival outcomes in biochemically recurrent prostate cancer.

4.Pharmacology & Molecular Identity

Leuprolide is a peptide-based molecule that is not orally bioavailable due to rapid degradation in the gastrointestinal tract. Consequently, it is administered via subcutaneous or intramuscular injection. Depot formulations are frequently utilized to provide a steady, controlled release of the drug over weeks or months, ensuring consistent suppression of the HPG axis.

5.Human Research Evidence

Human evidence for leuprolide is robust, particularly in the context of advanced prostate cancer, where it has been a standard of care for decades. Clinical trials have consistently demonstrated its ability to achieve castrate levels of testosterone within 3 to 4 weeks of initiation. Its efficacy in managing endometriosis and uterine fibroids is also well-documented in clinical literature.

6.Preclinical Research

Preclinical studies have been instrumental in mapping the HPG axis and the receptor-level desensitization caused by chronic GnRH agonist exposure. Animal models have provided the foundational data for the reversibility of fertility suppression and the pharmacokinetics of various depot delivery systems.

7.Safety & Research Limitations

The primary safety considerations involve the initial flare effect, which may exacerbate symptoms in patients with advanced disease. Common side effects include hot flashes, fatigue, and potential bone density loss due to prolonged sex steroid suppression. Cardiovascular risks and metabolic changes are monitored in long-term clinical settings.

8.Evidence Quality & Research Gaps

While the efficacy of leuprolide is well-established, research gaps remain regarding its long-term cognitive effects and its utility in non-oncological, non-reproductive conditions. Further studies are needed to optimize combination therapies and to better understand the variability in individual patient responses to long-term suppression.

9.Frequently Asked Questions

10.References

1.Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. The New England journal of medicine. 2023 Oct 19. DOI: 10.1056/NEJMoa2303974.PMID: 37851874
2.Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. The New England journal of medicine. 2020 Jun 4. DOI: 10.1056/NEJMoa2004325.PMID: 32469183
3.Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. The New England journal of medicine. 2026 Feb 5. DOI: 10.1056/NEJMoa2510310.PMID: 41124201
4.Authors not listed. Leuprolide. . 2012.PMID: 31643987
5.Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU international. 2008 Dec. DOI: 10.1111/j.1464-410X.2008.08183.x.PMID: 19035858
6.Lun T, Patel P, Gerriets V. Leuprolide. . 2026 Jan.PMID: 31869126
7.Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009 Oct 1. DOI: 10.2165/10484080-000000000-00000.PMID: 19747011
8.Rutgers J. Leuprolide-treated myomas. The American journal of surgical pathology. 1997 Apr. DOI: 10.1097/00000478-199704000-00021.PMID: 9131000
9.Tutrone R, Saad F, George DJ, Tombal B, Bailen JL. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European urology oncology. 2024 Aug. DOI: 10.1016/j.euo.2023.11.024.PMID: 38143206
10.Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R. Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age. European journal of cancer (Oxford, England : 1990). 2026 Jan. DOI: 10.1016/j.ejca.2025.116110.PMID: 41274168

Compound Command Center

Linked Research Evidence (0)

Published studies and registry summaries. Trial registration alone is not evidence of efficacy.

No linked research articles yet.